Browse 10 Iga Nephropathy Medical Studies Across 107 Cities
3 Phase 3 Trial · 187 Iga Nephropathy Clinics
What Are IgA Nephropathy Clinical Trials?
IgA nephropathy, also known as Berger's disease, is characterized by predominant IgA deposition in the glomerular mesangium. Simply put, it is a kidney disease in which IgA deposits build up in the kidney and cause inflammation that damages the kidney tissues. It affects the kidneys by attacking the glomeruli, which are sets of looping blood vessels in the nephrons. The buildup of IgA deposits inflames the glomeruli, causing the kidneys to leak blood and protein into the urine.
Many ongoing IgA nephropathy clinical trials study the efficiency of different drugs and treatments for positive outcomes.
Why Is IgA Nephropathy Being Studied Through Clinical Trials?
IgA nephropathy is one of the most common kidney diseases and can occur at any age. The incidence rate has been estimated at 2–10 per 100,000 person-years. In the U.S, IgA nephropathy is twice as likely to appear in men than in women, and while found in people all over the world, it is more common among Asians and Caucasians.
Moreover, the disease course ranges from asymptomatic nonprogressive to aggressive, with up to one in four patients suffering from ESRD within 20 years from diagnosis, requiring RRT. IgA nephropathy is a chronic kidney disease and can lead to end-stage renal disease.
What Are The Types of Treatments Available For IgA Nephropathy?
Treatments regarding IgA nephropathy are mostly centered around pharmacotherapy. A clinical trial is underway to study the efficiency and safety of LNP023 in primary IgA Nephropathy patients. The study will be pivotal for the registration of LNP023 in IgA Nephropathy patients who demonstrate a clinically meaningful reduction in proteinuria by LNP023 vs. placebo as assessed by reduction in urine protein to creatinine ratio (UPCR) sampled from a 24-hour urine collection at an IA at nine months.
Current treatment for IgA nephropathy includes antiplatelet and anticoagulant drugs.
What Are Some Recent Breakthrough Clinical Trials For IgA Nephropathy?
Following are some of the recent studies conducted on IgA nephropathy:
2011: Current Therapy for IgA Nephropathy - A small randomized trial suggested the benefit of dipyridamole (75 mg three times daily and warfarin [INR 1.3 to 1.5]) as compared with no treatment.
2019: Biomarkers for IgA Nephropathy - this study focuses on early diagnosis of the disease for curative treatment strategies and approaches. While the renal biopsy is commonly used, this study found that disease-oriented specific serum and urine biomarkers may help screen potential IgAN with isolated hematuria, earlier diagnosis, disease activity, and eventually, response to treatment.
Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting IgA Nephropathy Clinical Trial Research?
American Society Of Nephrology
The American Society Of Nephrology is the largest professional society that fights against kidney diseases by educating health professionals, sharing new knowledge, and advancing research.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIDDK conducts clinical trials to identify new ways to prevent, detect, or treat kidney diseases. It supports basic and clinical research on kidney development and disease, including causes, progression, identification, and testing of possible treatments.